0000000000391098

AUTHOR

Matteo Bonini

showing 16 related works from this author

Feasibility of the Allergy Questionnaire for Athletes (AQUA © ) in pediatric age

2018

A burden of respiratory and allergic symptoms up to almost 60% has been observed in young and adult athletes, influencing physical performances1 . The Allergy Questionnaire for Athletes (AQUA©) is a validated screening tool for the prediction of the atopic status in adult athletes2 ; it was recently tested in Belgian young elite athletes (12-14 years old)3 , but its actual feasibility and suitability for children and adolescent was not evaluated. Indeed, there is evidence that children are prone to employ "satisficing" response strategies, answering every question positively/negatively, or simply not answering4 . Therefore, the present cross-sectional survey was carried out to assess feasib…

medicine.medical_specialtyAllergyCross-sectional studyself-reports.ImmunologyMEDLINEAtopy03 medical and health sciences0302 clinical medicinemedicineImmunology and Allergy030212 general & internal medicineAsthmayoung athletesSettore M-EDF/02 - Metodi E Didattiche Delle Attivita' SportivebiologyAthletesbusiness.industrySettore MED/09 - MEDICINA INTERNAAQUA© questionnaireAdolescent; Athletes; Child; Cross-Sectional Studies; Feasibility Studies; Female; Humans; Hypersensitivity; Male; Sports; Surveys and Questionnaires; Pediatrics Perinatology and Child Health; Immunology and Allergy; ImmunologyPediatric ageself-reportsmedicine.diseasebiology.organism_classification030228 respiratory systemFamily medicinePediatrics Perinatology and Child Healthallergy symptoms AQUA© questionnaire feasibility linguistic adaptation young athletes missing answers self-reports.businessSettore M-EDF/01 - Metodi E Didattiche Delle Attivita' Motorieallergy symptomsfeasibilityPediatric Allergy and Immunology
researchProduct

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

2020

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored al…

ISAR International Severe Asthma RegistrySHARPPediatricsSevere asthmaSA severe asthmaBiologics Oral corticosteroids Real-life Registr Severe asthmaOmalizumabforced expiratory volume in the 1st secondFood &ampGrading of Recommendations Assessmentchronic rhinosinusitis with nasal polyposisFEV1chemistry.chemical_compound0302 clinical medicineQuality of lifeEMAReal WorldEuropean Medicines AgencyBiologics; Oral corticosteroids; Real-life; Registr; Severe asthmaOral corticosteroidsFDA Food & Drug AdministrationImmunology and Allergy030223 otorhinolaryngologySevere Heterogeneous Asthma Research collaborationmusculoskeletal neural and ocular physiologyReal-lifeCRSwNPOCSsBenralizumabDupilumabCRSwNP chronic rhinosinusitis with nasal polyposisGRADESHARP Severe Heterogeneous Asthma Research collaboration Patient-centredSevere Asthma Network in ItalyFDAmedicine.drugPulmonary and Respiratory Medicinelcsh:Immunologic diseases. Allergymedicine.medical_specialtyDrug AdministrationGINA Global Initiative for AsthmaRW Real WorldImmunologymacromolecular substancesRWSettore MED/10 - Malattie Dell'Apparato RespiratorioBiologicsInternational Severe Asthma RegistryISAR03 medical and health sciencesSADisease registrySARP Severe Asthma Research ProgramPatient-centredmedicineAsthmabusiness.industrySettore MED/09 - MEDICINA INTERNASANI Severe Asthma Network in ItalySANIBiological productmedicine.diseaseOCSs Oral CorticoSteroidsGINASARPSevere Asthma Research ProgramFEV1 forced expiratory volume in the 1st second030228 respiratory systemchemistrynervous systemRegistrEMA European Medicines AgencyDevelopment and EvaluationSevere asthma Biologics Oral corticosteroids Real-life Registrbusinesslcsh:RC581-607Global Initiative for AsthmaMepolizumabGRADE Grading of Recommendations Assessment Development and Evaluation
researchProduct

Allergic diseases in the elderly: biological characteristics and main immunological and non-immunological mechanisms

2017

Life expectancy and the number of elderly people are progressively increasing around the world. Together with other pathologies, allergic diseases also show an increasing incidence in geriatric age. This is partly due to the growing emphasis on a more accurate and careful diagnosis of the molecular mechanisms that do not allow to ignore the real pathogenesis of many symptoms until now unknown, and partly to the fact that the allergic people from 20 years ago represent the elderly population now. Moreover, environmental pollution predisposes to the onset of allergic asthma and dermatitis which are the result of internal pathologies more than the expression of allergic manifestations. At the …

0301 basic medicineAgingAllergyAllergyUrticariamedicine.medical_treatmentImmunologyEnvironmental pollutionReviewSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesElderlyImmune systemAnaphylaxiFood allergyFood allergymedicineImmunology and AllergyAnaphylaxisMolecular BiologyAsthmabusiness.industryConjunctivitiImmunotherapyConjunctivitismedicine.diseaseAsthmaDrug reaction030104 developmental biologyageAging; Allergy; Anaphylaxis; Asthma; Conjunctivitis; Drug reaction; Elderly; Food allergy; Immunotherapy; Urticaria; Immunology and Allergy; Immunology; Molecular BiologyImmunologyLife expectancyImmunotherapybusinessAnaphylaxisClinical and Molecular Allergy
researchProduct

WITHDRAWN: Scaling up strategies of the Chronic Respiratory Disease programme of the European Innovation Partnership on Active and Healthy Ageing (Ac…

2017

Gerontologymedicine.medical_specialtybusiness.industryRespiratory diseaseAlternative medicinemedicine.disease03 medical and health sciences0302 clinical medicine030228 respiratory systemGeneral partnershipAction planmedicineGeneral Earth and Planetary Sciences030212 general & internal medicineHealthy ageingbusinessGeneral Environmental ScienceAlergologia Polska - Polish Journal of Allergology
researchProduct

Minimal clinically important difference for asthma endpoints: an expert consensus report

2020

Minimal clinically important difference (MCID) can be defined as the smallest change or difference in an outcome measure that is perceived as beneficial and would lead to a change in the patient's medical management.The aim of the current expert consensus report is to provide a “state-of-the-art” review of the currently available literature evidence about MCID for end-points to monitor asthma control, in order to facilitate optimal disease management and identify unmet needs in the field to guide future research.A series of MCID cut-offs are currently available in literature and validated among populations of asthmatic patients, with most of the evidence focusing on outcomes as patient repo…

Asthma asthma management minimal clinically important difference end-pointsPulmonary and Respiratory Medicinemedicine.medical_specialtyConsensusDelphi TechniqueEndpoint DeterminationBronchoconstrictionMEDLINEDelphi methodSocio-culturaleSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOminimal clinically important difference; asthma; lung function; biomarkersMCID03 medical and health sciences0302 clinical medicinePredictive Value of TestsmedicineHumansAnti-Asthmatic Agents030212 general & internal medicineDisease management (health)Intensive care medicineLungAsthmalcsh:RC705-779business.industryMinimal clinically important differenceminimal clinically important differenceExpert consensusend-pointslcsh:Diseases of the respiratory systemmedicine.diseaseMCID asthmaAsthmaTreatment Outcome030228 respiratory systemPredictive value of testsEndpoint DeterminationInflammation MediatorsSymptom AssessmentbusinessBiomarkersasthma managementEuropean Respiratory Review
researchProduct

Tiotropium in asthma: Back to the future of anticholinergic treatment

2017

Abstract Asthma is among the most common chronic diseases worldwide; however, despite progresses in the understanding of the patho-physiological mechanisms and advances in the development of new therapeutic options and strategies, the disease remains uncontrolled in a not trivial proportion of subjects. Thus, the need of new molecules to treat the underlying biological and functional abnormalities and to control symptoms is strongly advocated by clinicians. In this scenario, the most recent GINA guidelines have included the use of tiotropium bromide in the most severe and uncontrolled forms of the disease, in addition to treatment with inhaled corticosteroid plus long acting beta adrenergic…

lcsh:Immunologic diseases. AllergyEndotypeAllergymedicine.medical_specialtyExacerbationmedicine.drug_classPopulationAntimuscarinicImmunologyReviewDiseaseAnticholinergicSettore MED/10 - Malattie Dell'Apparato RespiratorioEndotype03 medical and health sciences0302 clinical medicineControlmedicineAnticholinergicImmunology and Allergy030212 general & internal medicineeducationIntensive care medicineMolecular BiologyAsthmaeducation.field_of_studybusiness.industryTiotropiumExacerbationTiotropium bromidemedicine.diseaseAsthmaPhenotype030228 respiratory systemBronchodilationlcsh:RC581-607businessmedicine.drug
researchProduct

ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice: Review

2020

Submitted by (omml@ubi.pt) on 2021-07-05T10:37:14Z No. of bitstreams: 1 2021_Bousquet J_A_Anamorphosis.pdf: 1897974 bytes, checksum: 918eb581ab4e940b055ef8514f960e28 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T11:16:44Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_Anamorphosis.pdf: 1897974 bytes, checksum: 918eb581ab4e940b055ef8514f960e28 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T11:20:07Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_Anamorphosis.pdf: 1897974 bytes, checksum: 918eb581ab4e940b055ef8514f960e28 (MD5) Made available in DSpace on 2021-07-05T11:20:07Z (GMT). No. of bitstreams: 1 2021_Bousquet J_A_Anamorphosis.pdf: …

0301 basic medicineAllergyCARATComputer scienceIMPACTRespiratory Medicine and Allergy[SDV]Life Sciences [q-bio]computer.software_genreMedical and Health SciencesChange management (ITSM)Rhinitis.0302 clinical medicineQUALITY-OF-LIFEHDE ALERImmunology and AllergyLungmedicin och allergiSelf-managementRhinitis AllergicMultimediaAnamorphosisMOBILE TECHNOLOGYWORK PRODUCTIVITYdigital transformation of health and care3. Good healthsmernice ARIAAirway disease1107 ImmunologyGA(2)LENLife Sciences & BiomedicineASTHMA MULTIMORBIDITYe-zdravje600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und GesundheitARIA; asthma; CARAT; digital transformation of health and care; MASK; rhinitisSEASONAL ALLERGIC RHINITISMASKProcess (engineering)digital transformation of healthcareEUROPEAN INNOVATION PARTNERSHIPImmunologydigitalizacija zdravstvaARIA guidelines61003 medical and health sciencesQuality of life (healthcare)rhinitisHumansMobile technologyddc:610SELF-MANAGEMENTudc:616.2Science & TechnologyARIADigital transformationasthmaRespiration DisordersRhinitis AllergicMODEL030104 developmental biology030228 respiratory system3121 General medicine internal medicine and other clinical medicinee-healthClinical Medicinecomputer
researchProduct

Validity and repeatability of the Pediatric Allergy Questionnaire for Athletes (AQUAped) for the screening of atopy.

2020

BACKGROUND High atopy prevalence has been reported in athletes. Having an age-specific questionnaire for predicting atopy is important for an optimal management of young athletes. The study objectives were as follows: (i) developing a scoring system for the Pediatric Allergy Questionnaire for Athletes (AQUAped); (ii) identifying the optimal age target within the range 7-14 years; (iii) assessing AQUAped validity and repeatability in the identified target population. METHODS A total of 133 young athletes (age 7-14 years) were recruited. Following a screening visit, the participants filled AQUAped at baseline (T0) and after 7 days (T1), concomitantly undergoing skin prick testing. Using atopy…

medicine.medical_specialtyvalidityAdolescentImmunologyatopymedicine.disease_causeAtopy03 medical and health sciences0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticachildrenInternal medicineSurveys and QuestionnairesmedicineHypersensitivityImmunology and AllergyHumansMass Screening030212 general & internal medicinerepeatabilityChildSkin Testsyoung athletesReceiver operating characteristicbiologyAthletesbusiness.industryscreeningAQUApedInfant NewbornAeroallergenGold standard (test)Repeatabilitybiology.organism_classificationmedicine.diseaseOptimal management030228 respiratory systemAthletesPediatrics Perinatology and Child HealthPediatric allergybusinessPediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and ImmunologyREFERENCES
researchProduct

Anti-muscarinic drugs as preventive treatment of exercise-induced bronchoconstriction (EIB) in children and adults.

2020

Regular physical activity is strongly recommended to prevent chronic respiratory diseases, including asthma. On the other hand, vigorous physical training may trigger airway symptoms and bronchoconstriction. The transient airway narrowing occurring because of exercise is named exercise-induced bronchoconstriction (EIB). Despite management according to guidelines, a significant proportion of patients experiences uncontrolled EIB, which thus represents a relevant unmet medical need. In particular, although prevention and treatment of EIB are effectively based on the use of beta-2 bronchodilator drugs, high heterogeneity in individual responses has been reported. Furthermore, even though beta-…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAdolescentmedicine.drug_classBronchoconstrictionMuscarinic Antagonists03 medical and health sciencesYoung Adult0302 clinical medicineBronchodilatorAdministration InhalationRespiratory HypersensitivityMedicineAdrenergic DrugsHumans030212 general & internal medicineIntensive care medicineAdverse effectChildAsthmabusiness.industrymedicine.diseaseResponse VariabilityExercise-induced bronchoconstrictionBronchodilator AgentsAnti-muscarinic030228 respiratory systemDelayed-Action PreparationsSettore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREAnti muscarinicSystematic reviewBronchoconstrictionFemalemedicine.symptomAirwaybusinesshuman activitiesPhysical Conditioning HumanRespiratory medicine
researchProduct

Choosing wisely: Practical considerations on treatment efficacy and safety of asthma in the elderly

2015

The prevalence of asthma in the most advanced ages is similar to that of younger ages. However, the concept that older individuals may suffer from allergic asthma has been largely denied in the past, and a common belief attributes to asthma the definition of "rare" disease. Indeed, asthma in the elderly is often underdiagnosed or diagnosed as COPD, thus leading to undertreatment of improper treatment. This is also due to the heterogeneity of clinical and functional presentations of geriatric asthma, including the partial loss of reversibility and the lower occurrence of the allergic component in this age range. The older asthmatic patients are also characterized the coexistence of comorbid …

Allergymedicine.medical_specialtyAgingAllergyImmunologyAlternative medicineDiseaseReviewSettore MED/10 - Malattie Dell'Apparato RespiratorioAging; Allergy; Asthma; TherapymedicineImmunology and AllergyIntensive care medicineMolecular BiologyNon pharmacologicalAsthma...COPDbusiness.industryAging; Allergy; Asthma; Therapy; Molecular Biology; Immunology and Allergy; ImmunologySettore MED/09 - MEDICINA INTERNAmedicine.diseaseTreatment efficacyAsthmarespiratory tract diseasesClinical trialImmunologyTherapybusiness
researchProduct

Severe asthma: One disease and multiple definitions

2021

Abstract Introduction There is, so far, no universal definition of severe asthma. This definition usually relies on: number of exacerbations, inhaled therapy, need for oral corticosteroids, and respiratory function. The use of such parameters varies in the different definitions used. Thus, according to the parameters chosen, each patient may result in having severe asthma or not. The aim of this study was to evaluate how the choice of a specific definition of severe asthma can change the allocation of patients. Methods Data collected from the Severe Asthma Network Italy (SANI) registry were analyzed. All the patients included were then reclassified according to the definitions of U-BIOPRED,…

Pulmonary and Respiratory Medicinemedicine.medical_specialtySevere asthmaSevere asthmaImmunologyNiceDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioArticlePulmonary function testingInternal medicineBiological treatment; Classification; Definition; Severe asthmamedicineImmunology and AllergyRespiratory functioncomputer.programming_languageSevere asthma; Classification; Definition; Biological treatmentBiological therapiesbusiness.industrySettore MED/09 - MEDICINA INTERNADefinitionRC581-607ClassificationSevere asthma Classification Definition Biological treatmentBiological treatment Classification Definition Severe asthmaImmunologic diseases. AllergybusinessBiological treatmentcomputer
researchProduct

Targeting quality of life in asthmatic children: The MyTEP pilot randomized trial

2019

Abstract Background Quality of life (QoL) is an important outcome in the management of children with asthma. Mobile Health (m-Health) and Therapeutic Education Programs (TEPs) are increasingly recognized as essential components of pediatric asthma management to improve disease outcomes. Objective To evaluate the effect of an education program (MyTherapeutic Education Program, MyTEP) that couples multidisciplinary TEP intervention with an m-Health Program (mHP) in improving QoL in asthmatic children. Methods This single-center study employed a nonblinded randomized clinical trial design. Italian-speaking children (6–11 years) with mild-moderate asthma were eligible for participation. Partici…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyTherapeutic educationlaw.invention03 medical and health sciences0302 clinical medicinePatient Education as TopicQuality of lifeRandomized controlled trialRisk FactorsAsthma Children Quality of life Therapeutic education Mobile healthlawSurveys and QuestionnairesmedicineHumansMobile health030212 general & internal medicineChildChildrenAsthma Children Quality of life Therapeutic education Mobile healthAsthmaDescriptive statisticsbusiness.industrySmall sampleTherapeutic educationmedicine.diseaseAsthmaTelemedicineAsthmatic childrenItaly030228 respiratory systemSpirometrySmartphone appQuality of LifePhysical therapyFemalebusinessFollow-Up StudiesRespiratory Medicine
researchProduct

Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile techn…

2019

Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline by using the best approach to integrated care pathways using mobile technology in patients with allergic rhinitis (AR) and asthma multimorbidity. The proposed next phase of ARIA is change management, with the aim of providing an active and healthy life to patients with rhinitis and to those with asthma multimorbidity across the lifecycle irrespective of their sex or socioeconomic status to reduce health and social inequities incurred by the disease. ARIA has followed the 8-step model of Kotter to assess and implement the effect of rhinitis on asthma multimorbidity and to propose multimorbid guidelines. A second c…

AllergyAllergy:Medicina Básica [Ciências Médicas]asthma -- guidelineAllergic asthmaDECISION-MAKINGAllergic Rhinitis and Its Impact on AsthmaGUIDELINESMedical and Health SciencesMedical Records0302 clinical medicineHealth careImmunology and Allergy030212 general & internal medicineAllergic Rhinitis and Its Impact on Asthma; asthma; Change management; rhinitis; Immunology and Allergy; ImmunologyMASK-RHINITISComputingMilieux_MISCELLANEOUSRinitismobilne aplikacijeupravljanje spremembMedical recordGLOBAL STRATEGYWORK PRODUCTIVITYTelemedicinemobile applications3. Good healthAsma alérgicarhiniti1107 ImmunologyCiências Médicas::Medicina Básicaklinične potiallergic -- guidelineLife Sciences & BiomedicineHumanPATIENT PARTICIPATIONAllergic RhinitisTelemedicinemedicine.medical_specialtyanimal structuresmultimorbidityEUROPEAN INNOVATION PARTNERSHIPImmunologyChange Management[object Object]Settore MED/10 - Malattie Dell'Apparato RespiratorioAsthma/diagnosisCHRONIC DISEASESMACVIA-ARIA03 medical and health sciencesrhinitismedicinemultimorbidnostQUALITYHumanscritical pathwaysastma -- smernicaPatient participationAsmaudc:616.2AsthmaScience & TechnologyARIAbusiness.industryAllergic Rhinitis and Its Impact on Asthma; asthma; Change management; rhinitis; Change Management; Humans; Medical Records; Asthma; Multimorbidity; Rhinitis Allergic; TelemedicineSettore MED/09 - MEDICINA INTERNAchange managementMultimorbidityMobile Airways Sentinel Network (MASK) Study GroupGuidelineasthmata3121medicine.diseaseRinite alérgicaRhinitis AllergicRhinitis Allergic/diagnosisAsthmaIntegrated carealergijski rinitis -- smernicaAllergic Rhinitis and Its Impact on Asthma asthma Change management rhinitis Immunology and Allergy Immunology030228 respiratory systemFamily medicine3121 General medicine internal medicine and other clinical medicineMedical RecordClinical Medicinebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyImpact on AsthmaJournal of Allergy and Clinical Immunology
researchProduct

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

2021

Abstract Background and aims Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients. Methods Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017 and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months before mepolizumab were collected retrospectively. The evaluation parameters included: OCS use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual number of workin…

OR Odds RatioPediatricsSevere asthmaExacerbationAnti IL-5; Comorbidities; Mepolizumab; OCS; Pharmacoeconomics; Severe asthmagastroesophageal reflux diseaseSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOICS inhaled corticosteroidRate ratioOCS Oral Corticosteroidslaw.inventionComorbiditiesLAMA long acting muscarinic antagonist0302 clinical medicineRandomized controlled trialfractional nitric oxideInterquartile rangelawlong acting beta 2 agonistOdds RatioImmunology and AllergyRR Rate Ratio030223 otorhinolaryngologyPharmacoeconomicLOS Length of stayLOSIQRLAMAMEP MepolizumabORCISD Standard DeviationMEPPharmacoeconomicsACT Asthma Control TestComorbiditieCI Confidence Intervalsmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyinterquartile rangelong acting muscarinic antagonistImmunologyLABALABA long acting beta 2 agonistComorbidities Mepolizumab OCS Pharmacoeconomics Severe asthma Anti IL-5RRArticleRate Ratiochronic obstructive pulmonary disease03 medical and health sciencesPharmacoeconomicsOCS Oral CorticosteroidAsthma Control TestConfidence IntervalsFeNO fractional nitric oxideRCTs Randomized Controlled TrialmedicineCOPDGERD gastroesophageal reflux diseaseFeNOIQR interquartile rangeMepolizumabSDAsthmaRCTsOral Corticosteroidsbusiness.industryGERDmedicine.diseaseICS inhaled corticosteroidsACTComorbidityRandomized Controlled TrialsCI Confidence IntervalRCTs Randomized Controlled TrialsOCSCOPD chronic obstructive pulmonary disease030228 respiratory systemICSStandard DeviationLength of stayAnti IL-5inhaled corticosteroidslcsh:RC581-607businessMepolizumab
researchProduct

ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy

2021

Funding Information: BSreports personal fees from Allergopharma, during the conduct of the study; grants from National Health Programm, grant, personal fees from Polpharma, ASTRA, personal fees from Mylan, Adamed, patient ombudsman, national Centre for Research and Development, Polish Allergology Society. Funding Information: NGP reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer Ingelheim, grants from Gerolymatos International SA, Capricare. Funding Information: CA reports grants from Allergopharma, grants from Idorsia, Swiss National Science Foundation, Christine Kühne‐Center for Allergy Rese…

Pulmonary and Respiratory Medicineprecision medicineeducationImmunology610ReviewSettore MED/10 - Malattie Dell'Apparato Respiratorioimmune system diseasesHDE ALERallergic rhinitis ; asthma ; immunotherapy ; precision medicineMedicine and Health SciencesImmunology and Allergy[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/AllergologyComputingMilieux_MISCELLANEOUSRhinitisallergic rhinitisallergic rhinitis; asthma; immunotherapy; precision medicineasthmaRC581-607respiratory tract diseases3121 General medicine internal medicine and other clinical medicineimmunotherapyImmunologic diseases. Allergy600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergologyallergic rhinitis asthma immunotherapy precision medicine
researchProduct

Cabbage and fermented vegetables: from death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19

2021

International audience; Large differences in COVID-19 death rates exist between countries and between regions of the same country. Some very low death rate countries such as Eastern Asia, Central Europe, or the Balkans have a common feature of eating large quantities of fermented foods. Although biases exist when examining ecological studies, fermented vegetables or cabbage have been associated with low death rates in European countries. SARS-CoV-2 binds to its receptor, the angiotensin-converting enzyme 2 (ACE2). As a result of SARS-CoV-2 binding, ACE2 downregulation enhances the angiotensin II receptor type 1 (AT1 R) axis associated with oxidative stress. This leads to insulin resistance …

ARIA groupAntioxidantMediterranean dietmedicine.medical_treatmentBrassicasulforaphaneMESH: Angiotensin-Converting Enzyme 2ReviewcabbageAntioxidants0302 clinical medicine10183 Swiss Institute of Allergy and Asthma ResearchVegetableskimchiFood sciencekimči0303 health sciencesMESH: NF-E2-Related Factor 23. Good healthAngiotensin-converting enzyme 22723 Immunology and Allergyfermentirana zelenjavaMESH: EcologyKeywords: Angiotensin converting enzyme 2NF-E2-Related Factor 2KEAP1-NRF2 SYSTEMImmunologyReviewsBrassicaNRF203 medical and health sciencesudc:578:635.34:663.15:COVID‐19angiotensin-converting enzyme 2CorrespondenceHumansMESH: SARS-CoV-2LactobacilluINTERMITTENT HYPOXIA2403 ImmunologyScience & TechnologyMESH: HumansAngiotensin II receptor type 1koronavirusMESH: Antioxidantsmedicine.disease030228 respiratory systemchemistryFermentationAllergymedicine.disease_causechemistry.chemical_compoundLINKING GUT MICROBIOTALactobacillalesLactobacillusImmunology and AllergyMESH: COVID-19Angiotensin converting enzyme 2030212 general & internal medicineOXIDATIVE STRESS[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/AllergologyKeywords: Angiotensin converting enzyme 2; COVID-19; Lactobacillus; cabbage; diet; fermented vegetable; kimchi; sulforaphane.angiotensin-converting enzyme 2; cabbage; COVID-19; diet; fermented vegetable; kimchi; Lactobacillus; sulforaphane2. Zero hungerFOODSEcologyLactobacillalesMortality rate10177 Dermatology ClinicMEDITERRANEAN DIET1107 ImmunologyLife Sciences & Biomedicinefermented vegetable610 Medicine & healthSettore MED/10 - Malattie Dell'Apparato RespiratorioBiologyMESH: FermentationMESH: Gastrointestinal MicrobiomeInsulin resistanceMESH: DietDownregulation and upregulationmedicine030304 developmental biologySARS-CoV-2COVID-19MESH: BrassicaCOVID-19; Lactobacillus; angiotensin-converting enzyme 2; cabbage; diet; fermented vegetable; kimchi; sulforaphane; Angiotensin-Converting Enzyme 2; Antioxidants; COVID-19; Diet; Ecology; Gastrointestinal Microbiome; Humans; Lactobacillales; NF-E2-Related Factor 2; Brassica; Fermentation; SARS-CoV-2; Vegetablesbiology.organism_classificationMESH: VegetablesDYSFUNCTIONDietGastrointestinal MicrobiomeLactobacillusMESH: Lactobacillalesangiotensin-converting enzyme 2 cabbage COVID-19 diet fermented vegetable kimchi Lactobacillus sulforaphanedietOxidative stressSulforaphane
researchProduct